乳腺癌新辅助化疗前后ER、PR和HER-2表达的变化  

Changes of ER,PR and HER-2 expressions after neoadjuvant chemotherapy in breast cancer

作　　者：孙岩[1] 袁渊[1] 江伟[1] 曹国春[1] 陈颖波[1] 朱敬华[1] 

机构地区：[1]江苏省肿瘤医院内科,210009

出　　处：《江苏医药》2014年第23期2837-2838,共2页Jiangsu Medical Journal

基　　金：江苏省肿瘤医院院内课题(ZQ201101)

摘　　要：目的探讨雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2)在乳腺癌患者新辅助化疗前后的表达变化及临床意义。方法采用免疫组织化学染色法检测154例乳腺癌患者新辅助化疗前后的ER、PR和HER-2的表达变化。结果新辅助化疗前后的ER、PR和HER-2表达阳性率差异均无统计学意义(P>0.05);ER、PR和HER-2的阳性-阴性表达转化率分别为26.0%、28.0%和31.0%,以PR和HER-2丢失更为常见(P<0.05)。结论 ER、PR和HER-2的表达变化可作为指导乳腺癌新辅助化疗的重要指标。Objective To investigate the changes and clinical significance of the expressions of estrogen receptor（ER）,progesterone receptor（PR） and humanized epidermal growth factor receptor 2 （HER-2） before and after neoadjuvant chemotherapy （NAC） in the patients with breast cancer. Methods The changes of ER,PR and HER-2 expressions were detected by immunohistochemistry in 154 patients with breast cancer before and after NAC. Results The positive rates of ER, PR and HER-2 expressions before and after NAC were not statistically different （P^0. 05）. The conversion rates of positive and negative expression were 26.0%, 28. 0% and 31.0% for ER, PR and HER-2, respectively, in which the loss of PR and HER-2 was more common（P〈0. 05）. Conclusion The changes in ER, PR and HER-2 expressions may be the important indicators for pre- and post-NAC treatment in the patients with breast cancer.

关 键 词：乳腺癌 雌激素受体 孕激素受体 人表皮生长因子受体2 

分 类 号：R737[医药卫生—肿瘤]